Sanofi Reviews Diagnostics Strategy

6 April 1997

French health care and beauty products group Sanofi, which entered thediagnostics market in 1985 with the acquisition of part of Institut Pasteur Production, is reviewing its strategy in this business sector.

The firm's affiliate, Sanofi Diagnostics Pasteur - in which Sanofi has a 72% stake, has announced a partnership and sales agreement with Beckman Instruments of the USA. The deal relates to Beckman's automated Access equipment for immunoanalysis. Christian Policard, president of SDP, said this does not mean Sanofi is leaving the diagnostics market and added that diagnostics have synergies with the pharmaceuticals sector.

The Beckman deal includes a 10-year partnership to develop Access tests in France.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight